No Data
No Data
AIM Vaccine For Tetanus Gets NMPA's Nod; Shares Rise 5%
Express News | AIM Vaccine Has Obtained Clinical Approval for Two Heavyweight Products, Creating New Growth Points for Performance
Express News | AIM Vaccine - Second Generation of Highly-Effective Absorbed Tetanus Vaccine Obtained Clinical Trial Approval From Nmpa
AIM Vaccine Advances With New Influenza Vaccine Trial
Express News | AIM Vaccine Co - Suspension Culture Influenza Vaccine (Mdck Cells) Got Clinical Trial Approval From China's Nmpa
AIM Vaccine Co., Ltd. Showcases Innovation at 2024 Event
No Data